(ChemotherapyAdvisor) – The season of presentation announcements has begun for the annual meeting of the American Society of Clinical Oncology (ASCO), which will occur from June 1–5, 2012 in Chicago, IL. On May 8, 2012, Generex Biotechnology Corporation, Worcester, MA, announced that abstracts featuring the AE37 breast cancer vaccine clinical program of Generex wholly-owned subsidiary Antigen Express, Inc. will be presented at ASCO 2012.
Beginning on Saturday, June 2, from 8 a.m.–12 p.m. CDT, the company’s abstract entitled “An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase 2 trial” will be the subject of a poster presentation. Following this poster presentation will be an oral presentation based on an abstract entitled “From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines,” which will occur on Monday, June 4, 2012 at 5:30 pm CDT during the session on Developmental Therapeutics – Clinical Pharmacology and Immunotherapy.
In December 2011 Generex announced positive interim results of the ongoing Phase 2 clinical trial for the AE37 breast cancer vaccine. At the end of Phase 2, the company will begin conversations with the U.S. Food & Drug Administration (FDA) about the decision to move into Phase 3 trials.
Generex has collaborated with Antigen Express by coupling its RapidMist technology, which allows liquid formulations of drugs typically administered by injection to be absorbed through the oral mucosa, with the Antigen Express platform, which suppresses expression of the Ii protein in cancer cells, thus enabling potent stimulation of T-helper cells and preventing cancer cell growth.